Literature DB >> 23599410

Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response.

Tsutomu Sanaka1, Takahiro Mochizuki, Eriko Kinugasa, Eiji Kusano, Shigeru Ohwada, Tsutomu Kuno, Kenichiro Kojima, Shuzo Kobayashi, Minoru Satoh, Noriaki Shimada, Kazushi Nakao, Ryoichi Nakazawa, Hideki Nishimura, Eisei Noiri, Takashi Shigematsu, Tadashi Tomo, Teiryo Maeda.   

Abstract

BACKGROUND AND OBJECTIVES: A 1-year multicenter prospective randomized controlled study was conducted on the effects of vitamin E-bonded polysulfone dialyzers on erythropoiesis-stimulating agent response in hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Major inclusion criteria were use of high-flux polysulfone dialyzers with 50-70 ml/min β2-microglobulin clearance over 3 months, transferrin saturation over 20%, same erythropoiesis-stimulating agent for over 3 months, and hemoglobin at 10-12 g/dl. Hemodialysis patients were placed in four interventional groups: two hemoglobin ranges (10.0-10.9 or 11.0-11.9 g/dl) and two dialyzers. Patients were randomly assigned by central registration to a vitamin E-bonded polysulfone dialyzers or polysulfone control group. Primary end point was relative erythropoiesis resistance index at baseline between groups at 12 months. Erythropoiesis resistance index was defined as total weekly erythropoiesis-stimulating agent dose divided by hemoglobin.
RESULTS: There were no statistically significant differences in age or sex. There was no significant difference in relative erythropoiesis resistance index between vitamin E-bonded polysulfone dialyzers and control groups at 12 months (vitamin E-bonded polysulfone dialyzers: 1.1, control: 1.3). The vitamin E-bonded polysulfone dialyzers group showed better relative erythropoiesis resistance index than the control group at 11.0-11.9 g/dl hemoglobin (vitamin E-bonded polysulfone dialyzers: 1.0, control: 1.4 at 12 months, significant difference) but no difference at 10.0-10.9 g/dl hemoglobin.
CONCLUSIONS: The overall relative erythropoiesis resistance index showed no difference between the vitamin E-bonded polysulfone dialyzers and control groups, although the change in relative erythropoiesis resistance index differed according to hemoglobin level.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23599410      PMCID: PMC3675844          DOI: 10.2215/CJN.04680512

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study.

Authors:  S Huraib; D Tanimu; F Shaheen; F Hejaili; C Giles; V Pagayon
Journal:  Am J Nephrol       Date:  2000 Sep-Oct       Impact factor: 3.754

2.  International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.

Authors:  Philip A McFarlane; Ronald L Pisoni; Margaret A Eichleay; Ron Wald; Friedrich K Port; David Mendelssohn
Journal:  Kidney Int       Date:  2010-04-28       Impact factor: 10.612

3.  Analysis method and characterization of the antioxidant capacity of vitamin E-interactive polysulfone hemodialyzers.

Authors:  Alessandro Floridi; Marta Piroddi; Francesca Pilolli; Yutaka Matsumoto; Masaharu Aritomi; Francesco Galli
Journal:  Acta Biomater       Date:  2009-05-04       Impact factor: 8.947

Review 4.  Definition of high-performance membranes - from the clinical point of view.

Authors:  Akira Saito
Journal:  Contrib Nephrol       Date:  2011-08-08       Impact factor: 1.580

5.  Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy.

Authors:  K N Islam; D O'Byrne; S Devaraj; B Palmer; S M Grundy; I Jialal
Journal:  Atherosclerosis       Date:  2000-05       Impact factor: 5.162

6.  Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis--a molecular biological approach.

Authors:  L A Calò; A Naso; E Pagnin; P A Davis; M Castoro; R Corradin; P Riegler; C Cascone; W Huber; A Piccoli
Journal:  Clin Nephrol       Date:  2004-11       Impact factor: 0.975

7.  Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients.

Authors:  M Usberti; G Lima; M Arisi; G Bufano; L D'Avanzo; R M Gazzotti
Journal:  J Nephrol       Date:  1997 Sep-Oct       Impact factor: 3.902

8.  Plasma copper and antioxidant status in Wilson's disease.

Authors:  H Ogihara; T Ogihara; M Miki; H Yasuda; M Mino
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

9.  Improvement of intradialytic hypotension in diabetic hemodialysis patients using vitamin E-bonded polysulfone membrane dialyzers.

Authors:  Masahide Koremoto; Noriko Takahara; Masahiro Takahashi; Yasuhiro Okada; Kouhei Satoh; Tomoyoshi Kimura; Tomoyuki Hirai; Itaru Ebihara; Daisuke Nagasaku; Shigeo Miyata; Shunji Maniwa; Takuji Kouzuma; Tetsurou Arimura; Junzou Kamei
Journal:  Artif Organs       Date:  2012-07-30       Impact factor: 3.094

10.  The effect of vitamin E-bonded polysulfone membrane dialyzer on a new oxidative lipid marker.

Authors:  Yuki Kitamura; Kumi Kamimura; Noriko Yoshioka; Yoko Hosotani; Kenji Tsuchida; Masahide Koremoto; Jun Minakuchi
Journal:  J Artif Organs       Date:  2013-02-10       Impact factor: 1.731

View more
  2 in total

1.  Clinical evaluation of performance, biocompatibility, and safety of vitamin E-bonded polysulfone membrane hemodialyzer compared to non-vitamin E-bonded hemodialyzer.

Authors:  Mercedeh Kiaii; Masaharu Aritomi; Mitsuyo Nagase; Myriam Farah; Beverly Jung
Journal:  J Artif Organs       Date:  2019-06-26       Impact factor: 1.731

2.  A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane.

Authors:  Simon W Lines; Angela M Carter; Emma J Dunn; Elizabeth J Lindley; James E Tattersall; Mark J Wright
Journal:  Nephrol Dial Transplant       Date:  2013-11-28       Impact factor: 5.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.